Stingray Healthcare Featured In Healthcare Business International

Healthcare Business International (HBI) has featured Stingray Healthcare Group’s acquisition of the Centre de Cancérologie de la Porte de Saint-Cloud (CCPSC) in Paris, highlighting how the transaction strengthens the Group’s position in France and supports its strategy to build an integrated European oncology network.

The acquisition, completed through Stingray’s French subsidiary, Amethyst, further expands the Group’s presence in one of Europe’s largest oncology markets. 

CCPSC delivers radiotherapy services, preparation for chemotherapy and advanced treatment techniques, such as volumetric modulated arc therapy, while adhering to strict clinical quality and high safety standards.

The acquisition represents another step in Stingray’s long-term growth strategy across Europe. 

Private equity investor Fremman previously acquired Stingray and combined it with Amethyst Radiotherapy to create a pan-European cancer care platform spanning Austria, France, Germany, Italy, Poland, Portugal, Romania and the UK.

France remains one of Stingray’s key markets, driven by growing demand for cancer treatment in line with an ageing population and cancer rates on the rise. 

Currently, the country’s private oncology market is concentrated, among a small number of large providers, with Elsan alongside two other large groups cornering approximately of the market. 

The remainder is accounted for by several independent operators, many of which struggle where profitability is concerned. Approximately 60 per cent of treatment volumes are taken on by public providers, meanwhile. 

Speaking to Healthcare Business International, Ralph Hefti – Stingray CEO – observed that the CCPSC acquisition ties in well with the group’s overarching strategy of expanding access to oncology services, while building a network of specialist centres capable of delivering high-quality, integrated cancer care at scale.

He said: “Our ambition extends beyond radiotherapy. We are focused on developing comprehensive oncology services that support patients throughout their cancer journey, including radiotherapy, medical oncology, nuclear medicine, supportive care and other complementary services.

“By bringing together leading centres and expert clinical teams, we aim to create a network that delivers both clinical excellence and operational efficiency.”

Mr Hefti continued, explaining that the acquisition brings the first Zap-X system into the Stingray network. 

The robotic tool for non-invasive gyroscopic stereotactic radiosurgery, complementing the group’s established expertise in stereotactic radiosurgery, while further strengthening its advanced treatment capabilities.

Over time, the group intends to continue expanding its oncology offering beyond radiotherapy to include nuclear medicine, medical oncology and supporting care, creating more integrated cancer care pathways for patients across Europe.

As demand for cancer services continues to increase, healthcare systems across Europe face growing pressure from workforce shortages and capacity constraints.

Mr Hefti noted that these challenges present an excellent opportunity to improve patient access to care through continued investment in modern treatment infrastructure, advanced technologies and integrated pathways throughout the patient journey.

“There is also an opportunity to expand access to innovative treatments and personalised medicine,” he went on to say. 

“Advances in radiotherapy, imaging, artificial intelligence and precision oncology have the potential to significantly improve patient outcomes, but these innovations must be deployed at scale to maximise their impact.”

To find out more about Stingray’s outpatient cancer treatments and medical specialities, get in touch with the team today.